Introduction: Cervical cancer is one of the leading causes of cancer-related deaths among women in Brazil, primarily associated with persistent infection by the Human Papillomavirus (HPV). Although largely preventable through organized screening and vaccination programs, geographic and socioeconomic barriers in Pará—located in Brazil’s Northern Region—impede effective control. In 2023, the age-standardized incidence rate of cervical cancer in Brazil was approximately 11.34 cases per 100,000 women, with the Northern region being the most affected, with rates exceeding 17.96/100,000. In Pará, the estimated incidence was around 18.26 cases per 100,000 women, highlighting the urgent need for targeted interventions. Objectives: To analyze cervical cancer mortality data in the state of Pará from 2019 to 2023. Methods: An epidemiological, descriptive, and retrospective study was conducted using data from the Mortality Information System (SIM), obtained through the TABNET/DATASUS platform. Deaths due to malignant neoplasm of the cervix (ICD-10: C53) between 2019 and 2023 were included. Analyzed variables included year of death, age group, health region, race/skin color, education level, and sex. A descriptive temporal, demographic, and spatial analysis was performed, considering proportions and mortality rates. Results: During the study period, 1,912 cervical cancer deaths were recorded in Pará, all among women. The average annual mortality rate was 7.8 deaths per 100,000 inhabitants. The year 2022 had the highest number of deaths (417 deaths; 21.8%). The most affected age groups were 40–49 years (483 deaths; 25.3%), 50–59 years (388 deaths; 20.3%), and 60–69 years (332 deaths; 17.3%). Regionally, Metropolitan Region I accounted for 627 deaths (32.8%). Regarding race/skin color, most deaths occurred among mixed-race (parda) women (1,504 deaths; 78.6%). In terms of education level, women with 8–11 years of schooling were the most affected (496 deaths; 25.9%). Conclusion: Cervical cancer in Pará remains a significant cause of preventable mortality, reflecting important regional and socioeconomic inequalities. The disproportionate burden among middle-aged, mixed-race, and less-educated women indicates the urgent need to expand screening strategies, HPV vaccination coverage, and access to oncological care. Tailored public health policies are required to reduce mortality and inequities.
It is with great enthusiasm that we present the Annals of the Oncology International Symposium 2025, an event that continues to solidify its significance in the oncology landscape of northern Brazil. Held in Belém, Pará, Oncology 2025 centered around the theme "The cancer control challenge: better knowing it to best facing it," dedicating itself to exploring the latest frontiers in cancer treatment and prevention.
This year, the symposium provided a deep dive into the essential role of knowledge in the fight against cancer, presenting new perspectives and scientific advancements across various areas of oncology. Renowned global experts gathered to share their most recent research and innovative approaches, offering participants a comprehensive view of the challenges faced by healthcare professionals and patients worldwide.
Presentations and discussions during the event focused on critical topics such as the use of new technologies, advancements in personalized therapies, and more effective prevention strategies. Additionally, particular attention was given to the unique challenges faced by the Amazon region, with efforts aimed at developing region-specific solutions to meet local needs.
Beyond being a high-caliber academic event, Oncology 2025 stood out as a moment for integration and professional networking, with the warm hospitality of the city of Belém offering participants a unique experience. This event became a platform for exchanging ideas, where science, culture, and humanity came together in pursuit of a common goal: to improve cancer control both in Brazil and globally.
This collection of abstracts and articles presented during the event reflects the ongoing dedication to research and the development of innovative solutions, highlighting the importance of collaboration and shared knowledge in the fight against cancer.
General Submission Guidelines:
The presenting author, who does not have to be the first author, must be registered for Oncology 2025.
Each abstract may have up to 10 authors, including the main author and co-authors.
Only original, unpublished work will be accepted.
Submissions must be related to oncology. However, project descriptions, work proposals, experience reports, and literature reviews will not be considered.
Clinical case reports are allowed, provided the abstract addresses scientific questions, details clinical observations, and includes primary scientific data.
The abstract must be written in English, but presentations may be given in Portuguese.
Abstracts must be between 300 and 500 words.
Comissão Organizadora
Comissão Científica
See Annals of Oncology 2023 at:
https://www.even3.com.br/anais/oncology-2023-international-symposium/
Complete tool for submission, evaluation and publication of proceedings for scientific events.
